An immunosuppressant drug targeting sphingosine-1-phosphate was approved for the treatment of multiple sclerosis, due to its targeting ability towards sphingosine-1-phosphate receptors, but not towards serine palmitoyl transferase, in contrast to its parent compound myriocin [83]. This evidence concerns the gene S1PR1 and multiple sclerosis.